3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Arthritis, Rheumatoid
1
Interventions
Methotrexate
10
Adalimumab
6
tocilizumab
5
Rituximab
5
olokizumab
4
tofacitinib
3
Etanercept
3
golimumab
2
RC-18
2
Abatacept
2
veltuzumab
1
upadacitinib
1
secukinumab
1
sarilumab
1
mavrilimumab
1
baricitinib
1
andecaliximab
1
Tumor Necrosis Factor Inhibitors
1
TACI receptor-IgG Fc fragment fusion protein
1
Sulfasalazine
1
Pharmaceutical Preparations
1
Leflunomide
1
Interleukin 1 Receptor Antagonist Protein
1
Infliximab
1
ISIS104838
1
Hydroxychloroquine
1
Folic Acid
1
Double-Blind Method
1
Chloroquine
1
CT-P13
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Arthritis, Rheumatoid
×
Antirheumatic Agents
×
Clear all
NCT02046603
2018-12-07
ACT-MOVE
Hoffmann-La Roche
Phase 3
Completed
162 enrolled
30 charts